167 related articles for article (PubMed ID: 11134836)
1. T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer.
Nijman HW; van Diest PJ; Poort-Keesom RJ; von Mensdorff-Pouilly S; Verstraeten RA; Kummer A; Meijer CJ; Melief CJ; Hilgers J; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 2001 Jan; 94(1):114-20. PubMed ID: 11134836
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?
Kayser S; Watermann I; Rentzsch C; Weinschenk T; Wallwiener D; Gückel B
J Cancer Res Clin Oncol; 2003 Jul; 129(7):397-409. PubMed ID: 12836015
[TBL] [Abstract][Full Text] [Related]
3. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
Nielsen JS; Sahota RA; Milne K; Kost SE; Nesslinger NJ; Watson PH; Nelson BH
Clin Cancer Res; 2012 Jun; 18(12):3281-92. PubMed ID: 22553348
[TBL] [Abstract][Full Text] [Related]
4. Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions.
Bontkes HJ; de Gruijl TD; Walboomers JM; van den Muysenberg AJ; Gunther AW; Scheper RJ; Meijer CJ; Kummer JA
Br J Cancer; 1997; 76(10):1353-60. PubMed ID: 9374383
[TBL] [Abstract][Full Text] [Related]
5. Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma.
Townsend KN; Spowart JE; Huwait H; Eshragh S; West NR; Elrick MA; Kalloger SE; Anglesio M; Watson PH; Huntsman DG; Lum JJ
PLoS One; 2013; 8(12):e82406. PubMed ID: 24376535
[TBL] [Abstract][Full Text] [Related]
6. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
7. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
8. Hepatosplenic T cell lymphoma with no expression of cytotoxic molecules.
Sadahira Y; Notohara K; Manabe T
J Clin Pathol; 2003 Aug; 56(8):631-3. PubMed ID: 12890821
[TBL] [Abstract][Full Text] [Related]
9. Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B.
Morice WG; Kurtin PJ; Tefferi A; Hanson CA
Blood; 2002 Jan; 99(1):268-74. PubMed ID: 11756181
[TBL] [Abstract][Full Text] [Related]
10. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
Leffers N; Lambeck AJ; de Graeff P; Bijlsma AY; Daemen T; van der Zee AG; Nijman HW
Gynecol Oncol; 2008 Sep; 110(3):365-73. PubMed ID: 18571704
[TBL] [Abstract][Full Text] [Related]
11. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.
Milne K; Köbel M; Kalloger SE; Barnes RO; Gao D; Gilks CB; Watson PH; Nelson BH
PLoS One; 2009 Jul; 4(7):e6412. PubMed ID: 19641607
[TBL] [Abstract][Full Text] [Related]
12. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.
van Houdt IS; Sluijter BJ; Moesbergen LM; Vos WM; de Gruijl TD; Molenkamp BG; van den Eertwegh AJ; Hooijberg E; van Leeuwen PA; Meijer CJ; Oudejans JJ
Int J Cancer; 2008 Aug; 123(3):609-15. PubMed ID: 18498132
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients.
Alvaro-Naranjo T; Lejeune M; Salvadó-Usach MT; Bosch-Príncep R; Reverter-Branchat G; Jaén-Martínez J; Pons-Ferré LE
Leuk Lymphoma; 2005 Nov; 46(11):1581-91. PubMed ID: 16236613
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
[TBL] [Abstract][Full Text] [Related]
15. Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.
Zhang G; Xu Q; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Cancer Med; 2021 Jun; 10(12):3905-3918. PubMed ID: 33955198
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
17. Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study.
Brustmann H
Gynecol Oncol; 2004 Jan; 92(1):268-76. PubMed ID: 14751170
[TBL] [Abstract][Full Text] [Related]
18. Tumor antigens and antigen-presenting capacity in breast cancer.
McDermott RS; Beuvon F; Pauly M; Pallud C; Vincent-Salomon A; Mosseri V; Pouillart P; Scholl SM
Pathobiology; 2002-2003; 70(6):324-32. PubMed ID: 12865628
[TBL] [Abstract][Full Text] [Related]
19. Epithelial antigens in carcinomas of the ovaries. Relation to histological classification.
Jørgensen A; Nielsen K
APMIS; 1994 Jul; 102(7):533-7. PubMed ID: 7522476
[TBL] [Abstract][Full Text] [Related]
20. Expression of major histocompatibility antigens in human chronic pancreatitis.
Jalleh RP; Gilbertson JA; Williamson RC; Slater SD; Foster CS
Gut; 1993 Oct; 34(10):1452-7. PubMed ID: 8244120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
